Healthcare provider profile · identity verified

Janice Dara, MD

Allopathic & Osteopathic Physicians|Family Medicine · ALEXANDRIA, LA · NPI 1952757304

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Janice Dara, MD received $139.11 in general payments during 2025 across 2 reported records.

Lilly USA, LLC accounted for 89.8% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.

Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Myrbetriq by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 238 claims for Jardiance by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 221 claims for Mounjaro by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Trulicity by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$139.11

2 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Lilly USA, LLC	Unresolved — no canonical attribution shown	$124.98	89.8%	1	2025
Astellas Pharma US Inc	Unresolved — no canonical attribution shown	$14.13	10.2%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$139.11	2

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
MOUNJARO Normalized: mounjaro	Drug	Lilly USA, LLC	$124.98	1	2025
Source payment records 2025-10-23 · Lilly USA, LLC · $124.98 · Open Payments source
Veozah Normalized: veozah	Drug	Astellas Pharma US Inc	$14.13	1	2025
Source payment records 2025-09-11 · Astellas Pharma US Inc · $14.13 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
MOUNJARO mounjaro	2025	Mounjaro	2024	221	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Astellas Pharma US Inc Exact reporting entity; no affiliate inference	2025	Myrbetriq open payments reported associated product	CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014	Myrbetriq · 2024 Exact normalized brand match · 1 Part D row	37	11
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557	Jardiance · 2024 Exact normalized brand match · 1 Part D row	238	51
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	MOUNJARO open payments reported associated product	CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455	Mounjaro · 2024 Exact normalized brand match · 1 Part D row	221	41
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	TRULICITY open payments reported associated product	CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601	Trulicity · 2024 Exact normalized brand match · 1 Part D row	120	30

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	1141	173
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	602	73
Atorvastatin Calcium	Atorvastatin Calcium	499	160
Amlodipine Besylate	Amlodipine Besylate	484	143
Alprazolam	Alprazolam	480	77
Gabapentin	Gabapentin	469	123
Rosuvastatin Calcium	Rosuvastatin Calcium	415	123
Pantoprazole Sodium	Pantoprazole Sodium	370	110
Levothyroxine Sodium	Levothyroxine Sodium	325	75
Hydrochlorothiazide	Hydrochlorothiazide	250	71
Jardiance	Empagliflozin	238	51
Albuterol Sulfate Hfa	Albuterol Sulfate	227	64
Mounjaro	Tirzepatide	221	41
Potassium Chloride	Potassium Chloride	214	65
Montelukast Sodium	Montelukast Sodium	209	73
Metformin Hcl	Metformin Hcl	200	61
Lisinopril	Lisinopril	199	53
Losartan Potassium	Losartan Potassium	199	64
Oxycodone Hcl	Oxycodone Hcl	194	27
Tramadol Hcl	Tramadol Hcl	183	32
Omeprazole	Omeprazole	182	52
Furosemide	Furosemide	176	60
Metoprolol Succinate	Metoprolol Succinate	175	55
Zolpidem Tartrate	Zolpidem Tartrate	167	39
Duloxetine Hcl	Duloxetine Hcl	162	32
Allopurinol	Allopurinol	148	46
Ozempic	Semaglutide	147	25
Clopidogrel	Clopidogrel Bisulfate	139	41
Pregabalin	Pregabalin	138	32
Ezetimibe	Ezetimibe	136	41
Tamsulosin Hcl	Tamsulosin Hcl	134	38
Promethazine Hcl	Promethazine Hcl	131	12
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	127	38
Tizanidine Hcl	Tizanidine Hcl	125	25
Trazodone Hcl	Trazodone Hcl	120	35
Trulicity	Dulaglutide	120	30
Fluticasone Propionate	Fluticasone Propionate	116	55
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	107	36
Eliquis	Apixaban	107	19
Escitalopram Oxalate	Escitalopram Oxalate	106	35
Quetiapine Fumarate	Quetiapine Fumarate	103	18
Meloxicam	Meloxicam	100	32
Nifedipine Er	Nifedipine	98	29
Farxiga	Dapagliflozin Propanediol	96	19
Clonazepam	Clonazepam	92	20
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	92	28
Ondansetron Odt	Ondansetron	91	28
Linzess	Linaclotide	87	28
Celecoxib	Celecoxib	84	21
Azithromycin	Azithromycin	83	59
Metoprolol Tartrate	Metoprolol Tartrate	83	23
Meclizine Hcl	Meclizine Hcl	82	23
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	79	24
Sertraline Hcl	Sertraline Hcl	79	21
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	78	16
Fluconazole	Fluconazole	77	47
Spironolactone	Spironolactone	77	23
Carvedilol	Carvedilol	76	26
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	74	60
Doxycycline Hyclate	Doxycycline Hyclate	73	58
Hydralazine Hcl	Hydralazine Hcl	73	25
Pravastatin Sodium	Pravastatin Sodium	73	19
Donepezil Hcl	Donepezil Hcl	69	27
Atenolol	Atenolol	67	18
Buspirone Hcl	Buspirone Hcl	67	16
Bisoprolol Fumarate	Bisoprolol Fumarate	66	22
Glipizide	Glipizide	66	18
Rybelsus	Semaglutide	66	23
Simvastatin	Simvastatin	66	19
Methylprednisolone	Methylprednisolone	64	51
Prednisone	Prednisone	62	41
Triamcinolone Acetonide	Triamcinolone Acetonide	62	23
Methocarbamol	Methocarbamol	60	24
Metformin Hcl Er	Metformin Hcl	58	17
Bupropion Xl	Bupropion Hcl	57	12
Hydroxyzine Hcl	Hydroxyzine Hcl	57	14
Baclofen	Baclofen	55	18
Citalopram Hbr	Citalopram Hydrobromide	55	11
Diclofenac Sodium	Diclofenac Sodium	55	16
Fluoxetine Hcl	Fluoxetine Hcl	55	15
Ciprofloxacin Hcl	Ciprofloxacin Hcl	52	43
Entresto	Sacubitril/Valsartan	52	11
Glimepiride	Glimepiride	51	17
Ibuprofen	Ibuprofen	51	13
Valsartan	Valsartan	51	13
Carisoprodol	Carisoprodol	50	13
Alendronate Sodium	Alendronate Sodium	49	14
Aripiprazole	Aripiprazole	49	12
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	49	12
Memantine Hcl	Memantine Hcl	48	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	48	12
Synthroid	Levothyroxine Sodium	48	11
Chlorthalidone	Chlorthalidone	47	15
Diazepam	Diazepam	46	12
Esomeprazole Magnesium	Esomeprazole Magnesium	46	13
Famotidine	Famotidine	46	11
Xarelto	Rivaroxaban	45	suppressed
Eszopiclone	Eszopiclone	43	15
Clonidine Hcl	Clonidine Hcl	42	16
Dexlansoprazole Dr	Dexlansoprazole	40	suppressed
Lactulose	Lactulose	40	12
Mirtazapine	Mirtazapine	40	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	40	11
Levetiracetam	Levetiracetam	39	11
Myrbetriq	Mirabegron	37	11
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	37	13
Pioglitazone Hcl	Pioglitazone Hcl	37	14
Januvia	Sitagliptin Phosphate	36	12
Lorazepam	Lorazepam	36	suppressed
Estradiol	Estradiol	35	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	34	12
Dicyclomine Hcl	Dicyclomine Hcl	34	suppressed
Dropsafe Prep Pads	Alcohol Antiseptic Pads	33	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	33	suppressed
Lamotrigine	Lamotrigine	32	suppressed
Sucralfate	Sucralfate	32	12
Naproxen	Naproxen	29	suppressed
Ropinirole Hcl	Ropinirole Hcl	29	suppressed
Amoxicillin	Amoxicillin	28	20
Divalproex Sodium	Divalproex Sodium	28	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	28	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	28	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	27	11
Novolog Flexpen	Insulin Aspart	27	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	27	suppressed
Azelastine Hcl	Azelastine Hcl	26	11
Breo Ellipta	Fluticasone/Vilanterol	26	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	26	11
Finasteride	Finasteride	26	11
Clindamycin Hcl	Clindamycin Hcl	25	24
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	24	suppressed
Ventolin Hfa	Albuterol Sulfate	24	suppressed
Varenicline Tartrate	Varenicline Tartrate	23	12
Benazepril Hcl	Benazepril Hcl	22	suppressed
Ketoconazole	Ketoconazole	22	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	22	suppressed
Torsemide	Torsemide	22	13
Diltiazem 24hr Er	Diltiazem Hcl	21	suppressed
Dupixent Pen	Dupilumab	21	suppressed
Nebivolol Hcl	Nebivolol Hcl	21	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	21	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	20	suppressed
Carbamazepine	Carbamazepine	20	suppressed
Lovastatin	Lovastatin	20	suppressed
Nystatin	Nystatin	20	suppressed
Propranolol Hcl	Propranolol Hcl	20	suppressed
Temazepam	Temazepam	20	suppressed
Tresiba Flextouch U-100	Insulin Degludec	20	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	20	suppressed
Vraylar	Cariprazine Hcl	20	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	19	suppressed
Doxepin Hcl	Doxepin Hcl	19	suppressed
Mupirocin	Mupirocin	19	15
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	18	suppressed
Donepezil Hcl Odt	Donepezil Hcl	18	suppressed
Droplet Pen Needle	Pen Needle, Diabetic	18	suppressed
Levemir Flexpen	Insulin Detemir	18	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	18	14
Propranolol Hcl Er	Propranolol Hcl	18	suppressed
Symbicort	Budesonide/Formoterol Fumarate	18	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	18	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Emgality Pen	Galcanezumab-Gnlm	17	suppressed
Paroxetine Hcl	Paroxetine Hcl	17	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	17	16
Humalog	Insulin Lispro	16	suppressed
Morphine Sulfate Er	Morphine Sulfate	16	suppressed
Ranolazine Er	Ranolazine	16	suppressed
Verapamil Sr	Verapamil Hcl	16	suppressed
Olanzapine	Olanzapine	15	suppressed
Terazosin Hcl	Terazosin Hcl	15	suppressed
Topiramate	Topiramate	15	suppressed
Belsomra	Suvorexant	14	suppressed
Betamethasone Diprop Augmented	Betamethasone/Propylene Glyc	14	suppressed
Gemtesa	Vibegron	14	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	14	suppressed
Rexulti	Brexpiprazole	14	suppressed
Vascepa	Icosapent Ethyl	14	suppressed
Verapamil Er	Verapamil Hcl	14	suppressed
Clobetasol Propionate	Clobetasol Propionate	13	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	13	suppressed
Glipizide Er	Glipizide	13	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	13	suppressed
Levofloxacin	Levofloxacin	13	13
Nabumetone	Nabumetone	13	suppressed
Nitroglycerin	Nitroglycerin	13	suppressed
Nurtec Odt	Rimegepant Sulfate	13	suppressed
Risperidone	Risperidone	13	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	13	suppressed
Budesonide Er	Budesonide	12	suppressed
Chlorpromazine Hcl	Chlorpromazine Hcl	12	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	12	suppressed
Divalproex Sodium Er	Divalproex Sodium	12	suppressed
Lubiprostone	Lubiprostone	12	suppressed
Primidone	Primidone	12	suppressed
Testosterone Cypionate	Testosterone Cypionate	12	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	11	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	11	suppressed
Labetalol Hcl	Labetalol Hcl	11	suppressed
Lidocaine	Lidocaine	11	suppressed
Metolazone	Metolazone	11	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	11	11
Phenytoin Sodium Extended	Phenytoin Sodium Extended	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$139.11 · 2 records	Lilly USA, LLC	MOUNJARO, Veozah	4	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Mounjaro play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error